Schizophrenia and Related Disorders Clinical Trial
— LPOPOfficial title:
Linguistic Predictors of Outcomes in Psychosis
NCT number | NCT05601050 |
Other study ID # | 20-0460 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | March 4, 2021 |
Est. completion date | March 1, 2023 |
Verified date | March 2023 |
Source | Northwell Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Longitudinal observational study of the relationship between speech patterns and clinical symptoms in schizophrenia spectrum disorders.
Status | Completed |
Enrollment | 77 |
Est. completion date | March 1, 2023 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 40 Years |
Eligibility | Inclusion Criteria: - Speaks English with conversational proficiency - Current DSM-V-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, unspecified psychotic disorder, or brief psychotic disorder or bipolar 1 disorder with psychotic features or major depressive disorder with psychotic features using the Structured Clinical Interview for Axis I DSM-V Disorders (SCID-I/P). - Current significant positive or disorganized symptoms of psychosis (DSM 5 Criterion A) including rating at or above any of the following on the BPRS: - Grandiosity (Severe - 6) - Suspiciousness (Moderately Severe - 5) - Hallucinations (Moderately Severe - 5) - Unusual thought content (Moderate - 4) - Bizarre Behavior (Moderate - 4) - Disorientation (Moderate - 4) - Conceptual Disorganization (Moderate - 4) - Early phase of psychotic illness as defined by less than 2 years elapsed since reaching threshold for psychotic disorder - Age 15 to 40 years - Has capacity and willing to sign informed consent; if minor, parent is willing to give consent and child is willing to give assent. - Screening will not include a pregnancy test. Pregnant women will not be screened out of the study because the study procedures are of very low risk overall, and pregnancy does not place the participant or the fetus at any significant risk. - Minors will be included in the study because psychosis symptoms frequently onset before the age of 18 and this patient group is particularly in need of accurate prognosis and treatment. Therefore, it is of vital importance that the conclusions of the study be applicable to minors and that they be included among the participants. Exclusion Criteria: - Participants with substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, or shared psychotic disorder will not be included. - Patient currently under the influence of alcohol or drugs. - Disorders affecting speech or language, such as aphasia, intellectual disability (IQ<70), or language disorder, or movement disorders affecting speech like tardive dyskinesia, or physical impairments causing significant distortions to speech - Serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain and/or language, including but not limited to: neurodegenerative disorders, traumatic brain injury with active symptoms, autism spectrum disorder, encephalitis, epilepsy - Significant risk of suicidal or homicidal behavior; - Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Zucker Hillside Hospital | Glen Oaks | New York |
Lead Sponsor | Collaborator |
---|---|
Northwell Health | Winterlight Labs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Speech features from the Winterlight Speech Assessment | Acoustic and linguistic measures of speech computed based on performance on the Winterlight Speech Assessment. | 6 months | |
Secondary | Brief Psychiatric Rating Scale (BPRS) | 18 item, range = 1, not observed - 7, very severe; higher scores resulting in worse outcome. | 6 months | |
Secondary | Hamilton Rating Scale for Depression | 24 item, range = 0, absent - 4, severe; higher scores resulting in worse outcome. | 6 months | |
Secondary | Young Mania Rating Scale | 11 item, range = 0, absent - 8, severe; higher scores resulting in worse outcome. | 6 months | |
Secondary | Scale for the Assessment of Negative Symptoms | 22 item, range= 0, absent - 5, severe; higher scores resulting in worse outcome. | 6 months | |
Secondary | Scale for the Assessment of Thought Language and Communication | 20 item, range= 0, absent - 3, severe; higher scores resulting in worse outcome. | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05083377 -
Clozapine Use Pattern in the Province of Seville
|
||
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Recruiting |
NCT06134661 -
Accelerated rTMS for Psychomotor Slowing
|
N/A | |
Completed |
NCT01433094 -
Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia
|
N/A | |
Terminated |
NCT05526833 -
An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study
|
N/A | |
Recruiting |
NCT05982158 -
Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices
|
N/A | |
Active, not recruiting |
NCT06175559 -
Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia
|
N/A | |
Active, not recruiting |
NCT05673941 -
"InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia
|
N/A | |
Recruiting |
NCT02916810 -
TMS for Symptom Reduction in Schizophrenia
|
N/A | |
Recruiting |
NCT05958875 -
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
|
Phase 4 | |
Recruiting |
NCT03525054 -
Semantic and Syntactic Computerized Analysis of Free Speech
|
||
Recruiting |
NCT05389345 -
tDCS and Executive Function Training for Schizophrenia
|
N/A | |
Completed |
NCT03075202 -
Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
|
||
Completed |
NCT03921450 -
Overcoming Psychomotor Slowing in Psychosis (OCoPS-P)
|
N/A | |
Completed |
NCT06231407 -
Increasing Medication Check Participation Through Applying CT-r
|
N/A | |
Recruiting |
NCT04478838 -
"Extended" (Alternate Day) Antipsychotic Dosing
|
Phase 4 | |
Completed |
NCT04366401 -
Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders
|
N/A | |
Completed |
NCT04612777 -
A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses
|
N/A | |
Not yet recruiting |
NCT06191965 -
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
|
Phase 2/Phase 3 | |
Recruiting |
NCT04631939 -
Metacognitive Training as a Serious Game
|
N/A |